Buy Bpc 157, 20 mg
€39.33
BPC-157, 20 mg, is a synthetic GEPPPGKPADDAGLV pentadecapeptide for analytical and in vitro laboratory research. Pharma Research .eu provides documented European supply subject to lot-specific purity, identity and terminal-group verification.
Buy BPC-157, 20 mg, for Advanced Laboratory Research in Europe
BPC-157 is a synthetic 15-residue pentadecapeptide used as a laboratory reagent in peptide analytics, biochemical method development and controlled in vitro model systems. The commonly reported sequence is H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH, with formula C₆₂H₉₈N₁₆O₂₂ and an average molecular mass of approximately 1,419.5 Da. Pharma Research .eu presents this 20 mg format for qualified European laboratories requiring documented peptide materials.pubchem.ncbi.nlm.nih+1
Uncompromising Purity and Analytical Characterisation
BPC-157 should be specified as the linear pentadecapeptide:
H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH
The free N-terminus and free C-terminal carboxylic acid should be stated explicitly. Acetylated, amidated, phosphorylated or otherwise modified variants should not be treated as equivalent because they may have different molecular masses, charge states, chromatographic behaviour and assay characteristics.
For laboratory procurement, the suitable target is ≥99.0% purity by RP-HPLC, subject to confirmation by the actual batch-specific certificate of analysis. Some research references report ≥98% or higher, while individual vendors may specify ≥99%; the lot-specific chromatogram and release documentation should control acceptance.aminopeptides.co+1
A complete CoA should include:
-
RP-HPLC purity percentage, analytical method and chromatogram.
-
LC-MS, ESI-MS or high-resolution MS identity confirmation.
-
Full sequence and terminal-group designation.
-
Free-peptide, acetate or other salt-form information.
-
Molecular formula and molecular-mass assignment.
-
Visual appearance of the lyophilised material.
-
Residual-solvent results from synthesis and purification.
-
Water or residual-moisture content, where measured.
-
Heavy-metal or elemental-impurity results where included in the quality programme.
-
Lot number, manufacture date, retest date and storage requirements.
The commonly reported formula is C₆₂H₉₈N₁₆O₂₂, with average molecular mass approximately 1,419.5–1,419.56 g/mol and theoretical molecular weight around 1,419.54 Da. CAS Registry Number 137525-51-0 is widely reported, but the supplier should verify the exact terminal and salt form on the CoA.pubchem.ncbi.nlm.nih+2
BPC-157 is generally supplied as a white to off-white lyophilised powder. Visual inspection can identify gross discolouration, vial damage or visible contamination, but cannot establish identity or purity. Analytical release should combine visual assessment with RP-HPLC and mass-spectral confirmation.
High purity is important because the peptide contains multiple proline and glycine residues that may produce synthesis-related deletion sequences and closely related impurities. Additional species, water content and counter-ions can affect peak integration, ionisation, solubility and concentration calculations. Lower-grade or non-characterised material may therefore be unsuitable for quantitative LC-MS, stability-indicating methods or reproducible comparative research.
If a bacteriostatic-water component is supplied separately, it should have its own label, expiry date, preservative information and documentation. Preservatives can influence chromatography, ionisation, adsorption, pH and cellular assay performance.
Principal Laboratory Applications and Research Methodologies
BPC-157 is suitable for controlled laboratory research involving pentadecapeptide chemistry, analytical characterisation and in vitro biochemical model development. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.
RP-HPLC and LC-MS method development. BPC-157 can serve as a defined long-peptide analyte for retention-time assignment, intact-mass confirmation, impurity profiling and sample-recovery studies. Its polar, acidic sequence may require optimisation of mobile-phase pH, ionic strength, column chemistry and injection conditions.
Peptide identity and degradation profiling. Laboratories may monitor truncated sequences, oxidation products, hydrolysis-related species and other stress products using combined HPLC and mass spectrometry. The method should distinguish chemical degradation from adsorption to plastics, incomplete dissolution, matrix effects or instrument carryover.
In vitro biochemical and cellular models. A verified BPC-157 lot may be incorporated into controlled cell-free or cellular research systems examining peptide-associated signalling, barrier-model responses or tissue-biology pathways. Experimental plans should include vehicle controls, blank matrices, concentration confirmation and independent assessment of peptide integrity during incubation.
Reference and system-suitability applications. A documented batch may support instrument checks, calibration development, retention-time comparison and sample-preparation validation. Unless formally certified under a recognised reference-material standard, it should be described as a research reference material or analytical reagent rather than a certified reference material.
The 20 mg quantity corresponds to approximately 14.1 µmol using the reported average molecular mass of 1,419.5 g/mol. No final concentration should be stated because the reconstitution volume was not specified. Actual concentration depends on final volume, purity, salt form, water content and the validated laboratory preparation method.
Bacteriostatic water should not automatically be assumed suitable for every analytical or cellular workflow. Preservatives may require solvent blanks, matrix-effect studies and cell-compatibility testing. Laboratories should select and validate the reconstitution medium for the intended method.
Compound Stability, Optimal Storage, and Safe Handling Protocols
BPC-157 should remain sealed in its lyophilised state until required for a validated laboratory procedure. Research handling references commonly recommend storage of the dry material at approximately −20°C, protected from light and moisture. Some supplier guidance describes 2–8°C as acceptable for short-term sealed storage, but the lot-specific CoA and stability data should take precedence.pep-tek+2
Recommended controls include:
-
Store unopened lyophilised BPC-157 at approximately −20°C unless the CoA specifies otherwise.
-
Consider −80°C for extended archival storage where supported by the laboratory stability programme.
-
Keep the vial tightly closed, dry and protected from direct light.
-
Allow a sealed vial to reach room temperature before opening to minimise condensation.
-
Use low-binding tubes where adsorption could affect recovery.
-
Prepare aliquots if repeated vial access is expected.
-
Store short-term aqueous solutions at 2–8°C only where validated.
-
Use frozen aliquots for longer-term solution storage when supported by stability data.
-
Avoid repeated freeze–thaw cycles.
-
Record solvent, concentration, preparation date, operator and storage history.
Lyophilised BPC-157 is generally more stable than a prepared solution, but solution stability depends on pH, container material, concentration, temperature and exposure to light. Published or commercial statements about a fixed solution lifetime should not be treated as universal; laboratories should verify integrity with HPLC or LC-MS.
Reconstitution should be carried out using a validated laboratory procedure. Add the aqueous reagent gradually, allow the powder to hydrate and mix gently. Avoid vigorous agitation unless its compatibility has been demonstrated. Confirm concentration and chromatographic integrity after preparation where quantitative results are required.
Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and direct contact with the powder or solution. Dispose of contaminated materials through approved institutional chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | Specification |
|---|---|
| Product | BPC-157, 20 mg |
| Common designation | BPC-157; synthetic pentadecapeptide |
| Sequence | H-GEPPPGKPADDAGLV-OH |
| Residue count | 15 amino acids |
| IUPAC name | Full systematic peptide name should be confirmed on the CoA; sequence notation is preferred for procurement |
| CAS Registry Number | 137525-51-0 is widely reported; verify the exact form on the CoA |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ |
| Average molecular mass | Approximately 1,419.5–1,419.56 g/mol |
| Physical state and colour | Lyophilised white to off-white powder |
| Solubility profile | Aqueous reconstitution may be feasible; solvent and buffer compatibility require assay-specific validation |
| Typical purity | Proposed target ≥99.0% by RP-HPLC; verify the actual lot-specific result |
| Identity testing | LC-MS, ESI-MS or high-resolution MS |
| Long-term storage | Typically −20°C, sealed and protected from light and moisture |
The sequence, formula, molecular mass and CAS number are supported by PubChem and peptide-specification references. The supplier’s CoA should nevertheless control the final identity statement, particularly for terminal groups and salt form.pubchem.ncbi.nlm.nih+3
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can position BPC-157 as a documented European laboratory reagent for analytical chemists, biochemists and laboratory managers requiring a defined pentadecapeptide. The product file should include a batch-specific CoA, SDS, sequence designation, purity result, identity data, terminal-group and salt-form information, and storage instructions.
Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.
A quality-focused supplier should be able to discuss:
-
BPC-157’s GEPPPGKPADDAGLV sequence.
-
Free-peptide versus acetate or other salt form.
-
RP-HPLC purity and LC-MS identity testing.
-
Residual solvents, moisture and elemental-impurity reporting.
-
Packaging configuration and container-closure integrity.
-
Compatibility of any accompanying bacteriostatic water.
-
Storage, transport and documentation requirements.
Pharma Research .eu should therefore be described as a potential European source for research-grade BPC-157, with vendor-specific certification and logistics claims verified through current records. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.